Latest Articles
Clarivate Companies to Watch Report Spotlights Seven Women's Health Startups Shaping the Future of Care - The Malaysian Reserve
Clarivate Companies to Watch Report Spotlights Seven Women's Health Startups Shaping the Future of Care The Malaysian Reserve
Published: Nov. 13, 2025, 9:31 a.m.
Promega wins FDA approval as companion diagnostic for Keytruda-Lenvima combo in uterine cancer - Fierce Biotech
Promega wins FDA approval as companion diagnostic for Keytruda-Lenvima combo in uterine cancer Fierce Biotech
Published: Nov. 13, 2025, 9 a.m.
Amy Schumer reveals why she deleted pre-weight-loss posts on Instagram - NewsBytes
Amy Schumer reveals why she deleted pre-weight-loss posts on Instagram NewsBytes
Published: Nov. 13, 2025, 8:29 a.m.
Clarivate Companies to Watch Report Spotlights Seven Women's Health Startups Shaping the Future of Care - The Manila Times
Clarivate Companies to Watch Report Spotlights Seven Women's Health Startups Shaping the Future of Care The Manila Times
Published: Nov. 13, 2025, 8:24 a.m.
Seven companies forging new paths in women’s health - Clarivate
Seven companies forging new paths in women’s health Clarivate
Published: Nov. 13, 2025, 8:04 a.m.
Clarivate Companies to Watch Report Spotlights Seven Women's Health Startups Shaping the Future of Care - PR Newswire UK
Clarivate Companies to Watch Report Spotlights Seven Women's Health Startups Shaping the Future of Care PR Newswire UK
Published: Nov. 13, 2025, 8 a.m.
Dr. Richa Gangwar Advances Ovarian Rejuvenation, Brings New Hope for Women with Low Fertility in Lucknow - HindustanMetro.com
Dr. Richa Gangwar Advances Ovarian Rejuvenation, Brings New Hope for Women with Low Fertility in Lucknow HindustanMetro.com
Published: Nov. 13, 2025, 7:38 a.m.
What it’s like living in chronic pain as a woman - bodyandsoul.com.au
What it’s like living in chronic pain as a woman bodyandsoul.com.au
Published: Nov. 13, 2025, 7:18 a.m.
FDA Approves Promega OncoMate® MSI Dx as Companion Diagnostic for KEYTRUDA® and LENVIMA® in Endometrial Cancer - Voice Of HealthCare
FDA Approves Promega OncoMate® MSI Dx as Companion Diagnostic for KEYTRUDA® and LENVIMA® in Endometrial Cancer Voice Of HealthCare
Published: Nov. 13, 2025, 6:17 a.m.
FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma - 뉴스와이어
FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma 뉴스와이어
Published: Nov. 13, 2025, 5:50 a.m.
Link copied to clipboard!